




Attorney's Docket No.: M1015/7034 TJO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: R. Shoshana Bamdad and Cynthia C. Bamdad
Serial No.: 09/835,099
Filed: April 12, 2001
For: TREATMENT OF NEURODEGENERATIVE DISEASE

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231, on the 29 day of May, 2001.


Joan E. Meagher

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:


Transmitted herewith are the following documents:

Preliminary Amendment
 Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is believed due. If a fee is occasioned or if extensions of time are necessary, please charge the balance to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,



Timothy J. Oyer Reg. No. 36,628
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
Tel. (617)720-3500
Fax (617)720-2441

Docket No.: M1015/7034
Date: May 29, 2001




Attorney's Docket No.: M1015/7034 TJO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: R. Shoshana Bamdad and Cynthia C. Bamdad
Serial No.: 09/835,099
Filed: April 12, 2001
For: TREATMENT OF NEURODEGENERATIVE DISEASE

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231, on the 24 day of May, 2001.



Joak E. Meagher

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows. A marked-up version of the claims is attached hereto.

In the Claims

Please replace the claims as shown below. A marked-up version of the claims is attached hereto.

103. (Amended) A method as in claim 1, wherein the drug is selected from the group consisting of Atenolol, pindolol, histamine, methyl dihydrochloride, atenolol, 4-aminopyridine, physostigmine, and Tetracaine Hydrochloride.

104. (Amended) A method as in claim 1, wherein the drug is selected from the group consisting of sulpiride, uracil, 5-trifluoromethyl-5,6-dihydro, Atenolol, pindolol, BRL 37344 sodium, piperazine (2:1 ratio of 1-(4-hydroxy-3-methoxyphenyl)-1,2-ethanediol and diethyldiazene), cimetidine, methyl norepinephrine, oxotremorine methiodide, physostigmine, 4-aminopyridine, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one), and erbstatin analog.